Elanco Animal Health Incorporated (NYSE:ELAN) Receives $17.14 Average PT from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received an average recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $17.14.

A number of brokerages have weighed in on ELAN. Stifel Nicolaus restated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research note on Thursday, September 19th. Barclays increased their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Finally, Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $17.00 to $15.00 in a research report on Thursday, September 19th.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently bought and sold shares of the stock. Davidson Kempner Capital Management LP purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $839,000. Price T Rowe Associates Inc. MD boosted its holdings in Elanco Animal Health by 4.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,139,018 shares of the company’s stock valued at $360,425,000 after acquiring an additional 852,281 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $55,599,000. XTX Topco Ltd purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $935,000. Finally, SG Capital Management LLC purchased a new stake in Elanco Animal Health during the 1st quarter valued at about $4,211,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $13.13 on Thursday. The firm has a market capitalization of $6.49 billion, a P/E ratio of 33.10, a P/E/G ratio of 1.40 and a beta of 1.41. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The stock’s 50-day simple moving average is $13.66 and its two-hundred day simple moving average is $14.69. Elanco Animal Health has a twelve month low of $11.40 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 EPS. As a group, equities analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.